The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
How CDC Director Mandy Cohen is kicking off a new era
Why some states want more power over Medicare Advantage plans.
Congress not acting on the opioid epidemic
Why experts are criticizing FDA's approach to some neurological drugs
Why and how CMS is 'reining in' Medicare Advantage ads
How Bidens’ insurer transparency rules hinder shopping around
House speaker chaos, or not …
Biden’s NIH pick finally gets her confirmation hearing
What's behind Rep. McCaul's anti-fentanyl push?
Impact of Ohio’s vote on abortion rights
Sorting fact from fiction about Europe’s view of gender-affirming care
Hospitals targeted in Congress’ search for cost savings
The tuberculosis spike in NYC
Inside the Kaiser Permanente strike
Medicare kicks off its drug price negotiations with patient input
What you need to know about the stopgap spending bill
Why a government program meant to save Medicare money actually spent a lot more
Cancer care at a crossroads
Why hasn’t the Biden administration acted on a Trump-era health rule?
The American Medical Association’s growing rift with Republicans
Create your
podcast in
minutes
It is Free